Please login to the form below

Not currently logged in
Email:
Password:

GSK targets COPD adherence with integrated inhaler sensors

Hopes real-time patient experience data will improve clinical trial engagement
GSK

GlaxoSmithKline is set to begin a series of clinical trials focused on improving patient adherence to asthma and respiratory disease treatment.

Trial participants will use inhalers with clip-on sensors, which the firm hopes will provide real-time data that can be used to improve the patient experience.

GSK first teamed up with digital company Propeller Health in 2015 to develop the sensor, which was approved by the FDA as a companion device for its Ellipta treatment in November last year.

Using Bluetooth to relay insights to GSK's trial database, the sensor tracks how often patients take their medication and documents any obstructions that prevent patients from using the inhaler.

Ruth Tal-Singer, vice president of clinical discovery in respiratory research and development at GSK, told MM&M: “It's really the ability to tell whether someone is taking the medicine, to try to capture how patients feel, how active they are in the study.

“We need to hear the patient's voice and see how it works for them.”

The company hopes that remote monitoring will encourage people with asthma and chronic obstructive pulmonary disease (COPD) to get more involved in self-managing their condition, with real-time data enabling greater flexibility in meeting with medical professionals.

Tal-Singer added: “It really reduces the burden for patients, specifically individuals who are very sensitive to the environment.

“If it's a very cold day or there's a lot of pollution, it's difficult for someone with lung disease to come to the clinic. Instead of coming once a month or every two weeks, we can monitor how they are doing remotely.”

GSK is also set to begin Europe-wide rollout of the latest version of its asthma mobile app this year, which it first developed in 2012 to help patients monitor and understand the triggers for their asthma.

The MyAsthma app will now also be applicable to other therapy areas, driving the firm's focus on patient engagement to promote adherence.

Article by
Rebecca Clifford

3rd January 2017

From: Research

Share

Tags

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Purple Agency

An Integrated Marketing Communications Agency with a passion for Intelligent Strategy, Compelling Creativity and Professional Delivery....

Latest intelligence

Virtual Engagement At Porterhouse: Reflections on the past few months
A look at how the pitfalls of virtual engagement can be avoided and the key advantages of virtual client and KOL engagement strategies in a now predominantly digital world....
July 2020: diversity and inclusion in clinical trials round-up
COVID-19 has continued to bring diversity and health inequality to the forefront of people’s attention. Our latest round-up covers the July news around these issues, and brings you the latest...
Medical Device Clinical Trials 2020
In July 2020, we attended and exhibited at the Medical Device Clinical Trials 2020 Virtual Experience. We really enjoyed the day and it was great to hear from like-minded people,...

Infographics